While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab’s rigorous portfolio ...

Despite initial clinical data showing efficacy, Genmab has decided to discontinue further clinical development of HexaBody-CD38. “While we are disappointed that J&J has decided not to advance ...

(RTTNews) - Genmab A/S (GMAB) Monday announced that Johnson & Johnson (JNJ) has decided not to exercise its option to develop and commercialize HexaBody-CD38 for multiple myeloma, for a worldwide ...